Literature DB >> 9867164

Technetium-99m-labeled liposomes to image experimental colitis in rabbits: comparison with technetium-99m-HMPAO-granulocytes and technetium-99m-HYNIC-IgG.

E T Dams1, W J Oyen, O C Boerman, G Storm, P Laverman, E B Koenders, J W van der Meer, F H Corstens.   

Abstract

UNLABELLED: Scintigraphic techniques are routinely used for the evaluation of the extent and severity of inflammatory bowel disease. Currently, the radiopharmaceutical of choice is 99mTc-hexamethyl propyleneamine oxime (HMPAO)-leukocytes. We studied the imaging potential of two recently developed 99mTc-labeled agents, polyethylene glycol (PEG)-coated liposomes and hydrazinonicotinate (HYNIC) IgG, in a rabbit model of acute colitis, and compared them with that of 99mTc-labeled, granulocyte-enriched (>90%), white blood cells.
METHODS: Acute colitis was induced in rabbits by retrograde instillation of trinitrobenzene sulfonic acid. After 48 hr, 37 MBq of each radiopharmaceutical was administered intravenously. Gamma camera images were taken at 0, 1, 2, 4, 10 and 24 hr. At 4 and 24 hr postinjection, groups of rabbits were killed, and the uptake of the radiolabel in the dissected tissues was determined. For each affected 5-cm segment, the colitis index (CI, affected-to-normal-colon-uptake ratio) was calculated and correlated to the macroscopically scored severity of inflammation.
RESULTS: All three agents visualized the colitis lesions within 1 hr postinjection. The CI correlated with the severity of the abnormalities. With increasing severity, the CI at 4 hr postinjection for liposomes was 3.89+/-0.73, 4.41+/-0.47 and 5.76+/-0.65; for IgG 1.67+/-0.08, 3.92+/-0.44 and 6.14+/-0.65; and for granulocytes 2.90+/-0.09, 6.15+/-0.96 and 9.36+/-3.35. For liposomes, the CI further increased during 24-hr postinjection to 6.56+/-0.84, 8.50+/-0.53 and 10.61+/-1.34, respectively. The CI for the other two agents did not change significantly with time.
CONCLUSION: In this rabbit model, 99mTc-labeled granulocytes, IgG and liposomes all rapidly visualized colonic inflammation. Granulocytes and liposomes showed the highest CI. Technetium-99m-labeled PEG-liposomes may be an attractive alternative for labeled leukocytes to image inflammatory bowel disease, because they can be prepared off the shelf and no handling of blood is required.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9867164

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

Review 1.  Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Anticancer Agents Med Chem       Date:  2007-05       Impact factor: 2.505

2.  Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody.

Authors:  Jason L J Dearling; Eun Jeong Park; Patricia Dunning; Amanda Baker; Frederic Fahey; S Ted Treves; Sulpicio G Soriano; Motomu Shimaoka; Alan B Packard; Dan Peer
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

Review 3.  Nanomedicines in gastroenterology and hepatology.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 46.802

4.  Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue.

Authors:  R M Schiffelers; G Storm; I A Bakker-Woudenberg
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

5.  Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc-HYNIC IgG.

Authors:  E T Dams; M M Reijnen; W J Oyen; O C Boerman; P Laverman; G Storm; J W van der Meer; F H Corstens; H van Goor
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

Review 6.  Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine.

Authors:  Francis Man; Peter J Gawne; Rafael T M de Rosales
Journal:  Adv Drug Deliv Rev       Date:  2019-06-03       Impact factor: 15.470

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.